Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes - PubMed (original) (raw)
. 2007 Feb;81(4):1619-31.
doi: 10.1128/JVI.01580-06. Epub 2006 Nov 22.
Mathias Lichterfeld, Senica Chetty, Katie L Williams, Stanley K Mui, Toshiyuki Miura, Nicole Frahm, Margaret E Feeney, Yanhua Tang, Florencia Pereyra, Montiago X Labute, Katja Pfafferott, Alisdair Leslie, Hayley Crawford, Rachel Allgaier, William Hildebrand, Richard Kaslow, Christian Brander, Todd M Allen, Eric S Rosenberg, Photini Kiepiela, Madhu Vajpayee, Paul A Goepfert, Marcus Altfeld, Philip J R Goulder, Bruce D Walker
Affiliations
- PMID: 17121793
- PMCID: PMC1797559
- DOI: 10.1128/JVI.01580-06
Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes
Xu G Yu et al. J Virol. 2007 Feb.
Abstract
The relative contributions of HLA alleles and T-cell receptors (TCRs) to the prevention of mutational viral escape are unclear. Here, we examined human immunodeficiency virus type 1 (HIV-1)-specific CD8(+) T-cell responses restricted by two closely related HLA class I alleles, B*5701 and B*5703, that differ by two amino acids but are both associated with a dominant response to the same HIV-1 Gag epitope KF11 (KAFSPEVIPMF). When this epitope is presented by HLA-B*5701, it induces a TCR repertoire that is highly conserved among individuals, cross-recognizes viral epitope variants, and is rarely associated with mutational escape. In contrast, KF11 presented by HLA-B*5703 induces an entirely different, more heterogeneous TCR beta-chain repertoire that fails to recognize specific KF11 escape variants which frequently arise in clade C-infected HLA-B*5703(+) individuals. These data show the influence of HLA allele subtypes on TCR selection and indicate that extensive TCR diversity is not a prerequisite to prevention of allowable viral mutations.
Figures
FIG. 1.
Frequency of KF11 mutations in HIV-1 clade B- and clade C-infected individuals. Data are from clade C-infected individuals recruited from South Africa and India (A) and from clade B-infected persons from the United States and Europe (B). (C) HIV-1 RNA of clade C-infected HLA-B*5703-expressing individuals with KF11 wt, A2G-S4(N/K), or A2(G/S/N) sequences.
FIG. 2.
Cross-recognition of KF11 peptide variants in HLA-B*5701- or -B*5703-expressing individuals. (A and B) KF11 variants with amino acid substitutions at position 2, positions 2 and 4, or positions 3, 5, 7, or 10 were tested for recognition in a representative person expressing HLA-B*5701 (A) or HLA-B*5703 (B). (C) Cross-recognition of KF11 variants with single position 2 or combined position 2 and 4 mutations in individuals expressing HLA-B*5701 (seven of the patients described in Table 2 for whom sufficient PBMC samples were available) or HLA-B*5703 (eight of the patients described in Table 2 for whom sufficient samples were available). *, no IFN-γ secretion was observed at the highest peptide concentration tested.
FIG. 3.
Presentation of KF11 peptide variants on HLA-B*5701- and -B*5703-expressing antigen-presenting cells. (A) Target cell lysis of HLA-B*5701- or -B*5703-expressing B-LCL pulsed with KF11 wild type or variant peptides following exposure to a KF11-specific CD8+ T-cell clone restricted to HLA-B*5701 (Vβ19-CASTGTYGYT-J1.2; Vα5-CAASGGYQKVTFGTGTKLQVIP). (B) Drop-off rate of KF11 peptide variants from HLA-B*5701- or -B*5703-expressing B-LCL. Target cell lysis of HLA-B*5701- or -B*5703-expressing B-LCL by an HLA-B*5701-restricted CD8+ T-cell clone was measured either immediately after peptide pulsing (0 h) or after 12 or 36 h of resting. One representative experiment out of three is shown. (C) Proliferative responses of B*5701- or B*5703-restricted KF11-specific CD8+ T cells to stimulation with KF11 wt or KF11 A2G-S4(N/K) peptides, as measured by CFSE dilution assays. The right column indicates proliferative responses of HLA-B*5701-restricted KF11-specific CD8+ T cells stimulated with KF11 wt peptide or KF11 A2G-S4(N/K) peptide presented by B*5703-restricted B-LCL.
FIG. 3.
Presentation of KF11 peptide variants on HLA-B*5701- and -B*5703-expressing antigen-presenting cells. (A) Target cell lysis of HLA-B*5701- or -B*5703-expressing B-LCL pulsed with KF11 wild type or variant peptides following exposure to a KF11-specific CD8+ T-cell clone restricted to HLA-B*5701 (Vβ19-CASTGTYGYT-J1.2; Vα5-CAASGGYQKVTFGTGTKLQVIP). (B) Drop-off rate of KF11 peptide variants from HLA-B*5701- or -B*5703-expressing B-LCL. Target cell lysis of HLA-B*5701- or -B*5703-expressing B-LCL by an HLA-B*5701-restricted CD8+ T-cell clone was measured either immediately after peptide pulsing (0 h) or after 12 or 36 h of resting. One representative experiment out of three is shown. (C) Proliferative responses of B*5701- or B*5703-restricted KF11-specific CD8+ T cells to stimulation with KF11 wt or KF11 A2G-S4(N/K) peptides, as measured by CFSE dilution assays. The right column indicates proliferative responses of HLA-B*5701-restricted KF11-specific CD8+ T cells stimulated with KF11 wt peptide or KF11 A2G-S4(N/K) peptide presented by B*5703-restricted B-LCL.
FIG. 4.
Presentation of naturally processed KF11 peptide variants on HLA-B*5701- and -B*5703-expressing B-LCL. IFN-γ secretion by the same HLA-B*5701-restricted KF11-specific CD8+ T-cell clone was analyzed after stimulation with HLA-B*5701- or -B*5703-expressing B-LCL infected with vaccinia virus constructs encoding different KF11 variant sequences. In each case, one representative example with an effector:target ratio of 10:1 is shown.
Similar articles
- Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.
Payne RP, Branch S, Kløverpris H, Matthews PC, Koofhethile CK, Strong T, Adland E, Leitman E, Frater J, Ndung'u T, Hunter E, Haubrich R, Mothe B, Edwards A, Riddell L, Chen F, Harrigan PR, Brumme ZL, Mallal S, John M, Jooste JP, Shapiro R, Deeks SG, Walker BD, Brander C, Landis C, Carlson JM, Prado JG, Goulder PJ. Payne RP, et al. J Virol. 2014 May;88(9):4668-78. doi: 10.1128/JVI.03303-13. Epub 2014 Feb 5. J Virol. 2014. PMID: 24501417 Free PMC article. - Frequencies of Gag-restricted T-cell escape "footprints" differ across HIV-1 clades A1 and D chronically infected Ugandans irrespective of host HLA B alleles.
Serwanga J, Nakiboneka R, Mugaba S, Magambo B, Ndembi N, Gotch F, Kaleebu P. Serwanga J, et al. Vaccine. 2015 Mar 30;33(14):1664-72. doi: 10.1016/j.vaccine.2015.02.037. Epub 2015 Feb 26. Vaccine. 2015. PMID: 25728323 Free PMC article. - Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.
Payne RP, Kløverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, Sims S, Hickling S, Riddell L, Chen F, Luzzi G, Edwards A, Phillips R, Prado JG, Goulder PJ. Payne RP, et al. J Virol. 2010 Oct;84(20):10543-57. doi: 10.1128/JVI.00793-10. Epub 2010 Aug 4. J Virol. 2010. PMID: 20686036 Free PMC article. - HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural infection.
Bansal A, Gehre MN, Qin K, Sterrett S, Ali A, Dang Y, Abraham S, Costanzo MC, Venegas LA, Tang J, Manjunath N, Brockman MA, Yang OO, Kan-Mitchell J, Goepfert PA. Bansal A, et al. J Clin Invest. 2021 Aug 16;131(16):e148979. doi: 10.1172/JCI148979. J Clin Invest. 2021. PMID: 34228645 Free PMC article. - Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.
Bansal A, Yue L, Conway J, Yusim K, Tang J, Kappes J, Kaslow RA, Wilson CM, Goepfert PA. Bansal A, et al. AIDS. 2007 Nov 30;21(18):2387-97. doi: 10.1097/QAD.0b013e3282f13823. AIDS. 2007. PMID: 18025875 Free PMC article.
Cited by
- Protective HLA-B57: T cell and natural killer cell recognition in HIV infection.
Lobos CA, Downing J, D'Orsogna LJ, Chatzileontiadou DSM, Gras S. Lobos CA, et al. Biochem Soc Trans. 2022 Oct 31;50(5):1329-1339. doi: 10.1042/BST20220244. Biochem Soc Trans. 2022. PMID: 36111814 Free PMC article. Review. - Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers.
Lian X, Gao C, Sun X, Jiang C, Einkauf KB, Seiger KW, Chevalier JM, Yuki Y, Martin M, Hoh R, Peluso MJ, Carrington M, Ruiz-Mateos E, Deeks SG, Rosenberg ES, Walker BD, Lichterfeld M, Yu XG. Lian X, et al. Sci Transl Med. 2021 Dec 15;13(624):eabl4097. doi: 10.1126/scitranslmed.abl4097. Epub 2021 Dec 15. Sci Transl Med. 2021. PMID: 34910552 Free PMC article. - Interrogating the recognition landscape of a conserved HIV-specific TCR reveals distinct bacterial peptide cross-reactivity.
Mendoza JL, Fischer S, Gee MH, Lam LH, Brackenridge S, Powrie FM, Birnbaum M, McMichael AJ, Garcia KC, Gillespie GM. Mendoza JL, et al. Elife. 2020 Jul 27;9:e58128. doi: 10.7554/eLife.58128. Elife. 2020. PMID: 32716298 Free PMC article. - Challenging immunodominance of influenza-specific CD8+ T cell responses restricted by the risk-associated HLA-A*68:01 allomorph.
van de Sandt CE, Clemens EB, Grant EJ, Rowntree LC, Sant S, Halim H, Crowe J, Cheng AC, Kotsimbos TC, Richards M, Miller A, Tong SYC, Rossjohn J, Nguyen THO, Gras S, Chen W, Kedzierska K. van de Sandt CE, et al. Nat Commun. 2019 Dec 6;10(1):5579. doi: 10.1038/s41467-019-13346-4. Nat Commun. 2019. PMID: 31811120 Free PMC article. - HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome.
Illing PT, Pymm P, Croft NP, Hilton HG, Jojic V, Han AS, Mendoza JL, Mifsud NA, Dudek NL, McCluskey J, Parham P, Rossjohn J, Vivian JP, Purcell AW. Illing PT, et al. Nat Commun. 2018 Nov 8;9(1):4693. doi: 10.1038/s41467-018-07109-w. Nat Commun. 2018. PMID: 30410026 Free PMC article.
References
- Allen, T. M., M. Altfeld, X. G. Yu, K. M. O'Sullivan, M. Lichterfeld, S. Le Gall, M. John, B. R. Mothe, P. K. Lee, E. T. Kalife, D. E. Cohen, K. A. Freedberg, D. A. Strick, M. N. Johnston, A. Sette, E. S. Rosenberg, S. A. Mallal, P. J. Goulder, C. Brander, and B. D. Walker. 2004. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78:7069-7078. - PMC - PubMed
- Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, K. J. Kunstman, X. Wang, D. B. Allison, A. L. Hughes, R. C. Desrosiers, J. D. Altman, S. M. Wolinsky, A. Sette, and D. I. Watkins. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386-390. - PubMed
- Argaet, V. P., C. W. Schmidt, S. R. Burrows, S. L. Silins, M. G. Kurilla, D. L. Doolan, A. Suhrbier, D. J. Moss, E. Kieff, T. B. Sculley, and I. S. Misko. 1994. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 180:2335-2340. - PMC - PubMed
- Bankovich, A. J., and K. C. Garcia. 2003. Not just any T cell receptor will do. Immunity 18:7-11. - PubMed
- Barouch, D. H., J. Kunstman, M. J. Kuroda, J. E. Schmitz, S. Santra, F. W. Peyerl, G. R. Krivulka, K. Beaudry, M. A. Lifton, D. A. Gorgone, D. C. Montefiori, M. G. Lewis, S. M. Wolinsky, and N. L. Letvin. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335-339. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 AI060354/AI/NIAID NIH HHS/United States
- U01 HD040474/HD/NICHD NIH HHS/United States
- U01 HD040533/HD/NICHD NIH HHS/United States
- U01 HD40533/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials